1. A Retrospective Validation of International Consortium for MDS/MPN Response Criteria in CMML Treated with Hypomethylating Agents. (April 2017) Authors: Duchmann, M.; Braun, T.; Micol, J.B.; Platzbecker, U.; Park, S.; Pilorge, S.; Beyne-Rauzy, O.; Vey, N.; Sébert, M.; Gruson, B.; Dumas, P.Y.; Guieze, R.; Chretien, M.L.; Laribi, K.; Chait, Y.; Legros, L.; Hirsch, P.; Solary, E.; Fenaux, P.; Itzykson, R. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. GERMLINE CHEK2 MUTATED MDS PATIENTS. (May 2023) Authors: Freiman, L.; Larcher, L.; Tueur, G.; Vasquez, N.; Da Costa, M.; Raffoux, E.; Ades, L.; Fenaux, P.; Jean, S.; Duployer, N.; Clappier, E.; Sébert, M. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. GERMLINE DDX41 MUTATIONS : A SIGNIFICANT ENTITY WITHIN ADULT MDS/AML PATIENTS. (May 2023) Authors: Sébert, M. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: APPLICABILITY OF IPSS-M IN MYELODYSPLASTIC SYNDROMES ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA. (May 2023) Authors: Gurnari, C.; Prata, P.; Catto, L.F. Bazzo; Durmaz, A.; Larcher, L.; Sébert, M.; Allain, V.; Kewan, T.; Pagliuca, S.; Pinto, A.; Inacio, M.C.B.; Hernandez, L.; Dhedin, N.; Caillat-Zucman, S.; Clappier, E.; De Fontbrune, F.S.; Voso, M.T.; Visconte, V.; De Latour, R. Peffault; Jean, S. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗